These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36309856)

  • 1. Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kit.
    Duek A; Lellouche E; Ben Baruch S; Mashiach R; Segman Y; Bryk G; Leiba M
    Isr Med Assoc J; 2022 Oct; 24(10):629-633. PubMed ID: 36309856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
    Xu S; Liu Y; Wen L; Zhao L; Deng X; Rong R; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):840-845. PubMed ID: 34788924
    [No Abstract]   [Full Text] [Related]  

  • 3. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.
    Thoren KL; Pianko MJ; Maakaroun Y; Landgren CO; Ramanathan LV
    J Appl Lab Med; 2019 Mar; 3(5):857-863. PubMed ID: 31639760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations.
    Kirchhoff DC; Murata K; Thoren KL
    J Appl Lab Med; 2021 Nov; 6(6):1476-1483. PubMed ID: 34293131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
    van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
    Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
    Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
    Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma.
    Thoren K; Menad S; Nouadje G; Macé S
    J Appl Lab Med; 2024 Jul; 9(4):661-671. PubMed ID: 38573925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay.
    Rosenberg AS; Bainbridge S; Pahwa R; Jialal I
    Clin Biochem; 2016 Oct; 49(15):1202-1204. PubMed ID: 27475249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab.
    Jimenez A; Scholl AR; Wang B; Schilke M; Carlsen ED
    Clin Biochem; 2024 May; 127-128():110761. PubMed ID: 38565341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
    McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
    Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma.
    Lee HW; Kim SM; Park HD
    Clin Chem Lab Med; 2024 Oct; 62(11):2223-2232. PubMed ID: 38630027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
    Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
    Moore LM; Cho S; Thoren KL
    Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
    Jaskowski TD; Litwin CM; Hill HR
    Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring.
    Liu L; Wertz WJ; Kondisko A; Shurin MR; Wheeler SE
    J Appl Lab Med; 2020 Jan; 5(1):29-40. PubMed ID: 32445341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot Verification of a Novel Approach to Remove Electrophoretic Interference of the Therapeutic Monoclonal Antibody Daratumumab.
    Baloda V; Shurin MR; Wheeler SE
    J Appl Lab Med; 2022 Jun; 7(4):910-915. PubMed ID: 35060610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
    Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
    Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin class and light chain type of oligoclonal bands in CSF in multiple sclerosis determined by agarose gel electrophoresis and immunofixation.
    Link H; Laurenzi MA
    Ann Neurol; 1979 Aug; 6(2):107-10. PubMed ID: 115379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.